当前位置:首页 - 行情中心 - 恒瑞医药(600276) - 财务分析 - 现金流量表

恒瑞医药

(600276)

  

流通市值:2656.77亿  总市值:2658.77亿
流通股本:63.74亿   总股本:63.79亿

现金流量表

报告期2024-03-312023-12-312023-09-302023-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
销售商品、提供劳务收到的现金4,998,626,088.9824,093,922,387.9415,683,728,234.1311,508,327,824.89
收到的税费返还5,233,902.3565,619,728.7443,742,611.7530,038,928.3
收到其他与经营活动有关的现金1,132,191,375.651,295,530,285.4728,799,087.31606,882,363.75
经营活动现金流入的平衡项目0000
经营活动现金流入小计6,136,051,366.9825,455,072,402.0816,456,269,933.1912,145,249,116.94
购买商品、接受劳务支付的现金318,169,725.311,176,619,729.53837,496,649.53743,708,616.87
支付给职工以及为职工支付的现金1,532,162,227.175,752,122,784.164,411,153,993.323,022,383,571.27
支付的各项税费467,797,855.851,633,425,725.11,071,284,318.49923,729,349.76
支付其他与经营活动有关的现金2,563,322,649.659,249,239,088.775,827,463,790.934,580,079,109.67
经营活动现金流出的平衡项目0000
经营活动现金流出小计4,881,452,457.9817,811,407,327.5612,147,398,752.279,269,900,647.57
经营活动产生的现金流量净额平衡项目0000
经营活动产生的现金流量净额1,254,598,9097,643,665,074.524,308,871,180.922,875,348,469.37
二、投资活动产生的现金流量:
收回投资收到的现金-2,607,501,921.222,507,501,921.221,910,899,190.97
取得投资收益收到的现金9,009,741.4795,506,604.0489,493,013.5170,391,868.81
处置固定资产、无形资产和其他长期资产收回的现金净额1,621,876.5920,183,897.0613,232,187.474,359,000
投资活动现金流入的平衡项目0000
投资活动现金流入小计10,631,618.062,723,192,422.322,610,227,122.21,985,650,059.78
购建固定资产、无形资产和其他长期资产支付的现金561,021,859.61,483,791,745.291,370,472,925.79985,275,270.78
投资支付的现金200,000,00017,085,5702,167,7402,167,740
投资活动现金流出的平衡项目0000
投资活动现金流出小计761,021,859.61,500,877,315.291,372,640,665.79987,443,010.78
投资活动产生的现金流量净额平衡项目0000
投资活动产生的现金流量净额-750,390,241.541,222,315,107.031,237,586,456.41998,207,049
三、筹资活动产生的现金流量:
吸收投资收到的现金---750,470
取得借款收到的现金-21,100,00021,100,00010,000,000
筹资活动现金流入平衡项目-000
筹资活动现金流入小计-21,100,00021,100,00010,750,470
偿还债务支付的现金-1,281,100,0001,265,000,0001,260,000,000
分配股利、利润或偿付利息支付的现金-1,022,827,146.081,022,662,627.2983,482,349.16
支付其他与筹资活动有关的现金18,134,576.37861,599,151.46823,380,363.12389,083,592.5
筹资活动现金流出平衡项目0000
筹资活动现金流出小计18,134,576.373,165,526,297.543,111,042,990.322,632,565,941.66
筹资活动产生的现金流量净额平衡项目0000
筹资活动产生的现金流量净额-18,134,576.37-3,144,426,297.54-3,089,942,990.32-2,621,815,471.66
四、汇率变动对现金及现金等价物的影响-18,208,185.0112,533,137.6319,695,828.827,703,481.52
现金及现金等价物净增加额平衡项目0000
五、现金及现金等价物净增加额467,865,906.085,734,087,021.642,476,210,475.811,279,443,528.23
加:期初现金及现金等价物余额20,271,524,269.7214,537,437,248.0814,537,437,248.0814,537,437,248.08
期末现金及现金等价物余额平衡项目0000
期末现金及现金等价物余额20,739,390,175.820,271,524,269.7217,013,647,723.8915,816,880,776.31
补充资料:
净利润-4,277,820,702.5-2,290,405,823.55
资产减值准备-107,216,559.21--
固定资产和投资性房地产折旧-628,419,634.97-277,059,737.22
其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-628,419,634.97-277,059,737.22
无形资产摊销-38,096,588.6-13,137,257.91
长期待摊费用摊销-89,301,645.12-42,699,513.58
处置固定资产、无形资产和其他长期资产的损失--3,162,510.78--2,607,859.52
固定资产报废损失-6,213,109.52-1,835,135.87
公允价值变动损失-58,256,927.73-27,623,041.85
财务费用-5,903,776.07-8,174,342.92
投资损失--22,636,165.55--28,587,392.24
递延所得税--98,470,631.06--197,169.31
其中:递延所得税资产减少--81,658,728.99-4,952,940.2
递延所得税负债增加--16,811,902.07--5,150,109.51
存货的减少-129,105,750.3-47,249,456.92
经营性应收项目的减少-2,035,943,518.21-138,974,926.23
经营性应付项目的增加-315,322,509.87--30,317,131.51
其他-55,468,728.69-90,051,310.37
现金的期末余额-20,271,524,269.72-15,816,880,776.31
减:现金的期初余额-14,537,437,248.08-14,537,437,248.08
公告日期2024-04-182024-04-182023-10-262023-08-19
审计意见(境内)标准无保留意见
TOP↑